Participated · Series D · Sep 2024

Qure.ai is a global AI health innovator whose software analyses chest X-rays, CT scans, point-of-care ultrasounds, and other medical images to flag conditions such as tuberculosis, pneumonia, lung cancer, stroke, and other neuro-critical findings. The company’s platforms are deployed in more than 4,800 sites across 105+ countries, helping clinicians and health workers shorten TB diagnosis times from roughly two weeks to just one to two days, even in remote regions with limited clinical staff. Its technology is already used on Mount Everest, in sub-Saharan Africa, and rural Southeast Asia to bring diagnostics to hard-to-reach populations. Qure.ai’s product suite supports early disease detection, triage, and care-pathway management for both public-health programs and commercial healthcare providers. The firm also collaborates with pharmaceutical and medical-device companies to accelerate research and treatment developments. Looking ahead, Qure.ai plans to build an open-source, multi-modal database and new AI algorithms for point-of-care ultrasound, further expanding its lung-health capabilities. Although the article does not disclose current revenue figures, the multimillion-dollar Gates Foundation grant underscores external confidence in Qure.ai’s impact and future growth trajectory.

Participated · Equity · Nov 2023

Jana Care develops a digitally connected point‑of‑care platform that enables real‑time testing using fingerstick blood samples at home for management of heart failure, chronic kidney disease and diabetes. The company is developing quantitative tests for NT‑proBNP, potassium and serum creatinine—biomarkers critical to managing kidney and heart disease patients. Jana Care says it will use the new funding to expand development of its quantitative blood testing platform. It has established a product development and production facility in Bangalore, India. The company is led by CEO Anh Hoang‑Lindsay and is based in Watertown, MA. Jana Care recently completed an initial closing of a $6M financing round.

Participated · Equity · Aug 2023

MediBuddy is an Indian digital healthcare platform operating in the healthtech space. The company offers digital healthcare services. It announced it has secured $18 million in funding. The capital came from existing investors Quadria Capital, Lightrock and TEAMFund. The announcement did not disclose the financing instrument, valuation, or operating metrics such as revenue or user counts. No additional future plans or transaction terms were provided in the report. MediBuddy is an end-to-end digital healthcare platform that provides 24x7 access to specialist doctors via video calls, doorstep medicine delivery, at-home lab tests, mental health support and other integrated services. Led by CEO Satish Kannan and based in Bangalore, the platform has catered to the healthcare needs of over 3 crore Indians. The company’s core product integrates telemedicine, diagnostics and pharmacy fulfillment into a single user experience. Following the Series C, MediBuddy plans to invest in customer awareness and hiring. It also intends to strengthen its technology platforms, including data science capabilities, and to fund clinical research and product development. MediBuddy is a digital healthcare platform with a partner network comprising doctors, hospitals, diagnostic centres and pharmacies across India. The company raised Rs 25 crore in a venture debt round led by Stride Ventures. MediBuddy will use the funds to further strengthen its technology, operations and marketing. The financing came as venture debt, not equity. Stride Ventures is a venture debt fund that recently launched its second fund with a target corpus of over Rs 1,000 crore and has disbursed over Rs 200 crore since January. The company operates in the Indian digital healthcare market. MediBuddy is a digital healthcare platform. The company announced it has closed a $40 million Series B funding round. The financing was led by India Life Sciences Fund III, LLC. The round included participation from other, unnamed investors. The announcement was reported in India and provided no additional operational or revenue metrics. No further details on use of proceeds or prior rounds were disclosed in the article. MediBuddy DocsApp, formed by the merger of Bengaluru-based DocsApp and MediBuddy, is a digital healthcare platform providing online specialist doctor consultations, lab tests, preventive health checks and medicine delivery. The joint entity serves over three crore Indians via a partner network of more than 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres and 2,500 pharmacies, covering over 95% of Indian pin codes. It targets both enterprise and retail customers and aims to deliver an on-demand healthcare platform with strong customer experience. The company plans to use new funding to strengthen its doctor base, patient reach, product, and technology. Leadership said the merger will help establish market leadership and advance the mission of providing high-quality healthcare to a billion people.

Participated · Series B · Mar 2020

Founded in 2014 by interventional cardiologist Dr. Charit Bhograj, Tricog Health builds multimodal AI models that interpret ECG and ultrasound signals to detect up to 140 cardiac conditions in real time. Its flagship solutions—InstaECG™, InstaEcho™, and the Keebo™ cardiovascular AI platform—are integrated into 12,500+ clinics and hospitals across more than 12 countries in Asia and Africa. To date, the company has screened over 31 million patients and identified about 1 million critical cardiac cases, making it one of the world’s most widely used cardiovascular AI systems. Tricog pairs its AI analytics with a team of more than 100 in-house clinical specialists to streamline diagnosis and activate standardized care pathways from hospital to home. The firm is collaborating with global device makers, including OMRON Healthcare, to expand remote monitoring and guideline-directed therapy optimization. Its stated goal is to make quality heart care accessible to 100 million people by 2030. No revenue or profitability figures were disclosed in the article.